Verily, an Alphabet company focused on precision health, is pleased to announce the appointment of Utpal Koppikar as their new Chief Financial Officer. With an extensive background in finance, Koppikar brings a wealth of knowledge and expertise to the company and is well-positioned to lead Verily’s financial operations and strategy into the future.
Utpal has achieved remarkable success in the field of finance in the life sciences sector. Most recently, he served as Executive Vice President and Chief Financial Officer at Atara Biotherapeutics, a pioneering company in T-cell immunotherapy for cancer and autoimmune diseases. During his tenure, he effectively managed the finance, information technology and investor relations departments.
Utpal Patel is a finance industry veteran with a wealth of experience. He is currently the Chief Financial Officer at Atara Biotherapeutics, and has previously held several senior financial leadership positions at Gilead Sciences, including Vice President of Corporate and Operations Finance. During his time there, he was instrumental in leading the three-year financial planning process and financial integration of Kite Pharma. Prior to Gilead, Utpal served multiple finance roles of increasing responsibility at Amgen. His expertise is also sought after on the board of C4 Therapeutics and he was previously a board member of Flexion Therapeutics Inc., until its sale to Pacira Biosciences Inc. Utpal is a trusted financial leader whose insights and guidance are invaluable to the success of organizations.
Verily is excited to welcome Utpal to the team, tapping into his decades of financial and life sciences expertise. With his addition, Verily is well-positioned to accelerate its precision health strategy and close the gap between research and care with increasingly connected solutions. Stephen Gillett, Chief Executive Officer of Verily, is delighted to have Utpal on board to help drive Verily’s sustainable, long-term growth.
Joining Verily at this pivotal moment is an exciting opportunity for Utpal Koppikar, as he is inspired by Stephen and the leadership team’s vision to make precision health a commercial success. With the unwavering commitment of investors and the financial resources to invest in research, care, and precision risk management, Verily has the potential to revolutionize the lives of patients.
Verily is thrilled to have Utpal join the team, bringing with him decades of expertise in both financial and life sciences. Utpal’s addition to the Verily team will help to accelerate their precision health strategy and bridge the gap between research and care with a more connected approach to healthcare. Stephen Gillett, Chief Executive Officer of Verily, is delighted to have Utpal on board to spur on sustainable and long-term growth for the company.
We are thrilled to welcome Utpal to the Verily team and leverage his decades of expertise in finance and life sciences. With his addition, Verily is well-prepared to close the gap between research and care with increasingly connected solutions, and further accelerate its precision health strategy. Stephen Gillett, Chief Executive Officer of Verily, is ecstatic to have Utpal on board to help drive Verily’s long-term, sustainable growth, following his own appointment as CEO at the start of the year and the announcement of a refined strategy and product portfolio in late January. Last September, Verily raised $1 billion in an investment round led by Alphabet.
Verily is a subsidiary of Alphabet that is revolutionizing healthcare delivery and management with a data-driven, people-first approach. Established in 2015 as an initiative of X, Verily is on a mission to bring the power of precision health to everyone, every day. Verily gathers and activates data from clinical, social, behavioral and real-world sources to create personalized solutions that lead to better health outcomes. Equipped with cutting-edge technology, data science, and healthcare expertise, Verily is at the forefront of transforming healthcare delivery and management.